Characteristics and Risk Profile of Adult Patients Treated with Apremilast Included in the British Association of Dermatologists Biologic Interventions Register (BADBIR) : A Retrospective Database Analysis (20210230)

Study identification

• EU PAS number:
  EUPAS46337
• Study ID:
  50015
• Official title and acronym:
  Characteristics and Risk Profile of Adult Patients Treated with Apremilast Included in the British Association of Dermatologists Biologic Interventions Register (BADBIR) : A Retrospective Database Analysis (20210230)
• DARWIN EU® study:
  No
• Study countries:
  Ireland

  United Kingdom
• Study status:
  Finalised

Research institutions and networks

Institutions

Amgen

United States

Multiple centres: 164 centres are involved in the study

Study timelines

Date when funding contract was signed

Actual:12/12/2017

Study start date

Actual:12/12/2017

Data analysis start date

Actual:06/01/2022

Date of final study report

Planned:01/02/2023

Actual:01/03/2023

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Amgen

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable